Skip to main content

Advertisement

SpringerLink
Log in

Establishment and characterization of NCC-PS1-C1: a novel cell line of pleomorphic sarcoma from a patient after neoadjuvant radiotherapy

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Pleomorphic sarcoma (PS) is a heterogeneous group of malignant mesenchymal tumors without a specific histological lineage of differentiation. PS is genetically characterized by genetic instability and diversity and histologically characterized by morphological pleomorphism. PS is one of the most common soft tissue sarcomas. The only curative treatment for PS is complete surgical resection, in which neoadjuvant radiotherapy is frequently combined. PS demonstrates both local recurrence and metastasis after surgical treatment, and effective systemic chemotherapy has not yet been established. Patient-derived cancer cell lines are critical tools for basic and preclinical studies in the development of chemotherapy. However, only six PS cell lines are available from the public cell bank, and none of them are derived from PS after neoadjuvant radiotherapy, despite the fact that radiotherapy causes changes in the posttreatment cancer genome. Here, we reported a novel cell line of PS from a primary tumor specimen resected after neoadjuvant radiotherapy and named it NCC-PS1-C1. NCC-PS1-C1 cells showed a variety of copy number alterations and pathological mutations in TP53. NCC-PS1-C1 cells demonstrated constant proliferation, spheroid formation, and invasion capability in vitro. The screening of antitumor agents in NCC-PS1-C1 cells showed that bortezomib and romidepsin were effective against PS. In conclusion, we report a novel PS cell line from a primary tumor resected after neoadjuvant radiotherapy. We believe that NCC-PS1-C1 will be a useful tool for the development of novel chemotherapies for PS, especially for recurrent cases after neoadjuvant radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Carvalho SD, Pissaloux D, Crombé A, Coindre JM, Le Loarer F. Pleomorphic sarcomas: the state of the art. Surg Pathol Clin. 2019;12:63–105.

    Article  PubMed  Google Scholar 

  2. Hornick JL. Subclassification of pleomorphic sarcomas: How and why should we care? Ann Diagn Pathol. 2018;37:118–24.

    Article  PubMed  Google Scholar 

  3. Toulmonde M, Lucchesi C, Verbeke S, et al. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine. 2020;62: 103131.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chen S, Huang W, Luo P, et al. Undifferentiated pleomorphic sarcoma: long-term follow-up from a large institution. Cancer Manag Res. 2019;11:10001–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250–66.

    Article  CAS  PubMed  Google Scholar 

  6. Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006;48:51–62.

    Article  CAS  PubMed  Google Scholar 

  7. Wakely PE Jr. Cytopathology of myxofibrosarcoma: a study of 66 cases and literature review. J Am Soc Cytopathol. 2021;10:300–9.

    Article  PubMed  Google Scholar 

  8. Gervais MK, Callegaro D, Gronchi A. The evolution of adjuvant/neoadjuvant trials for resectable localized sarcoma. J Surg Oncol. 2022;125:17–27.

    Article  PubMed  Google Scholar 

  9. Keung EZ, Tsai JW, Ali AM, et al. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018;7: e1385689.

    Article  PubMed  Google Scholar 

  10. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859–68.

    Article  CAS  PubMed  Google Scholar 

  11. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21:2719–25.

    Article  PubMed  Google Scholar 

  12. Vodanovich DA, Spelman T, May D, Slavin J, Choong PFM. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases. ANZ J Surg. 2019;89:1045–50.

    Article  PubMed  Google Scholar 

  13. Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5:60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346:1480–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74:2377–84.

    Article  CAS  PubMed  Google Scholar 

  17. Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14:3–13.

    Article  CAS  PubMed  Google Scholar 

  18. Hideyuki T, Yoko T, Daisuke M, Miharu K, Tohru M, Hiroshi M. Cell line individualization by str multiplex system in the cell bank found cross-contamination between ECV304 and EJ-1/T24. Tissue Cult Res Commun. 1999;18:329–38.

    Google Scholar 

  19. Masters JR, Thomson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA. 2001;98:8012–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Drexler HG, Dirks WG, MacLeod RA, Uphoff CC. False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal. Int J Cancer. 2017;140:1209–14.

    Article  CAS  PubMed  Google Scholar 

  21. Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma. Hum Cell. 2020;33:427–36.

    Article  PubMed  Google Scholar 

  22. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941–7.

    Article  CAS  PubMed  Google Scholar 

  23. Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110:1480–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mohseny AB, Machado I, Cai Y, et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest. 2011;91:1195–205.

    Article  PubMed  Google Scholar 

  26. Klijn C, Durinck S, Stawiski EW, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015;33:306–12.

    Article  CAS  PubMed  Google Scholar 

  27. Dutil J, Chen Z, Monteiro AN, Teer JK, Eschrich SA. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 2019;79:1263–73.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569:503–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope. 2001;111:696–701.

    Article  CAS  PubMed  Google Scholar 

  30. Li GZ, Okada T, Kim YM, et al. Rb and p53-deficient myxofibrosarcoma and undifferentiated pleomorphic sarcoma require Skp2 for survival. Cancer Res. 2020;80:2461–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kocakavuk E, Anderson KJ, Varn FS, et al. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nat Genet. 2021;53:1088–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008;68:2551–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Carneiro A, Francis P, Bendahl PO, et al. Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Lab Invest. 2009;89:668–75.

    Article  CAS  PubMed  Google Scholar 

  34. Oyama R, Kito F, Sakumoto M, et al. Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. In Vitro Cell Dev Biol Anim. 2018;54:257–63.

    Article  CAS  PubMed  Google Scholar 

  35. Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-UPS3-C1: a novel patient-derived cell line of undifferentiated pleomorphic sarcoma. Hum Cell. 2022;35:384–91.

    Article  CAS  PubMed  Google Scholar 

  36. Ono T, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome. Hum Cell. 2022;35:756–66.

    Article  CAS  PubMed  Google Scholar 

  37. Kito F, Oyama R, Sakumoto M, et al. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Hum Cell. 2019;32:214–22.

    Article  CAS  PubMed  Google Scholar 

  38. Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Hum Cell. 2021;34:246–53.

    Article  CAS  PubMed  Google Scholar 

  39. Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34:1266–73.

    Article  CAS  PubMed  Google Scholar 

  40. Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34:1911–8.

    Article  CAS  PubMed  Google Scholar 

  41. Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-MFS5-C1: a novel patient-derived cell line of myxofibrosarcoma. Cells. 2022;11:207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Liu J, Zhao R, Jiang X, Li Z, Zhang B. Progress on the application of bortezomib and bortezomib-based nanoformulations. Biomolecules. 2021;12:51.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Li CF, Wang JM, Kang HY, et al. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin Cancer Res. 2012;18:1598–610.

    Article  CAS  PubMed  Google Scholar 

  44. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18:1414.

    Article  PubMed Central  Google Scholar 

  45. Saitoh Y, Bureta C, Sasaki H, et al. The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1. Mol Carcinog. 2019;58:234–46.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Drs. F. Nakatani, S. Iwata, S. Fukushima, T. Komatsubara (Department of Musculoskeletal Oncology), Drs. C. Sato, H. Tanaka, T. Shibayama (Department of Diagnostic Pathology) and the National Cancer Center Hospital for sampling tumor tissue specimens from surgically resected materials. We also appreciate the technical assistance provided by Mrs. Y. Kuwata (Division of Rare Cancer Research), and the technical support provided by Mrs. Y. Shiotani, Mr. N. Uchiya, and Dr. T. Imai (Central Animal Division, National Cancer Center Research Institute). We would like to thank Editage (www.editage.jp) for providing English language editing services and for their constructive comments on the manuscript. This research was technically assisted by the Fundamental Innovative Oncology Core in the National Cancer Center.

Funding

This research was supported by the Japan Agency for Medical Research and Development (grant number: 20ck0106537h0002).

Author information

Author notes

  1. Yuki Yoshimatsu

    Present address: Division of Patient-Derived Cancer Model, Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, Tochigi, 320-0834, Japan

Authors and Affiliations

  1. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Taro Akiyama, Yuki Yoshimatsu, Rei Noguchi, Yooksil Sin, Ryuto Tsuchiya, Takuya Ono & Tadashi Kondo

  2. Department of Orthopaedic Surgery, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, 260-0856, Japan

    Taro Akiyama, Ryuto Tsuchiya & Seiji Ohtori

  3. Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Jun Sugaya, Eisuke Kobayashi & Akira Kawai

  4. Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Akihiko Yoshida

Authors
  1. Taro Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuki Yoshimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rei Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yooksil Sin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryuto Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takuya Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Sugaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eisuke Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Seiji Ohtori
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Akira Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tadashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethics approval

The Ethical Committee of the National Cancer Center approved the use of clinical materials for this study (approval number 2004–050). Animal experiments were conducted in compliance with the guidelines of the Institute for Laboratory Animal Research, National Cancer Center Research Institute.

Informed consent

Written informed consent was provided by the patient.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

13577_2022_787_MOESM1_ESM.tiff

Supplementary file1 Supplementary Fig. 1 Short tandem repeat patterns of NCC-PS1-C1 (passage 21) and original tumor tissue. (a) Short tandem repeat patterns of NCC-PS1-C1 and (b) short tandem repeat patterns of original tumor tissue of NCC-PS1-C1 (TIFF 3923 KB)

Supplementary file2 (XLSX 15 KB)

Supplementary file3 (XLSX 12 KB)

Supplementary file4 (XLSX 11 KB)

Supplementary file5 (XLSX 23 KB)

Supplementary file6 (XLSX 25 KB)

Supplementary file7 (XLSX 12 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akiyama, T., Yoshimatsu, Y., Noguchi, R. et al. Establishment and characterization of NCC-PS1-C1: a novel cell line of pleomorphic sarcoma from a patient after neoadjuvant radiotherapy. Human Cell 35, 2011–2019 (2022). https://doi.org/10.1007/s13577-022-00787-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-022-00787-1

Keywords

Search

Navigation